3[9]Poli D,Antonucei E,Cecchi E,et al.Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation:the role of homocysteine[J].Stroke,2005,36(10):2159-2163.
4[10]Fang MC,Singer DE,Chang Y,et al.Gender differences in the risk of ischemie stroke and peripheral embolism inatrial fibrillation:the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study[J].Circulation,2005,112(12):1687-1691.
5[11]Lip GY,Hart RG,Conway DS.Antithrombotic therapy for atrial fibrillation[J].BMJ,2002,325 (7371):1022-1025.
6[12]Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC2006 guidelines for the management of patients with atrial fibrillation-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)[J].J Am Coil Cardiol,2006,48(4):854906.
7[13]Go AS,Fang MC,Singer DE.Antithrombotic therapy for stroke prevention in atrial fibrillation[J].Prog Cardiovasc Dis,2005,48(2):108-124.
8[14]Economides Munoz C,Singh BN.Antithrombotic therapies for stroke prevention in atrial fibrillation[J].Minerva Cardioangiol,2004,52 (2):125-139.
9[15]O'Donnell M,Weitz JI.Emerging therapies for stroke prevention in atrial fibrillation[J].Eur Heart J,2005,7(Suppl C):C19-C27.
10[16]Ostermayer SH,Reisman M,Kramer PH,et al.Percutaneous left atrial appendage transcatheter occlusion(PLAATO system)to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation:results from the international multi-center feasibility trials[J].J Am CoilCardiol,2005,46(1):9-14.
